CAREDX INC (CDNA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for CDNA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CDNA | Independent Director | 59 | ["20+ years of executive management experience in the pharmaceutical and diagnostic industry","Risk management expertise","M&A or corporate development experience"] | ["Technology and Innovation Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Independent Director Age: 59 Independent Director since 2024 Committees: Technology and Innovation Committee Professional Experience CEO, Kyverna Therapeutics (Nasdaq: KYTX) (2022 - 2024) Executive Chairman, CareDx (Nasdaq: CDNA) (2020 - 2021) CEO & President, CareDx (Nasdaq: CDNA) (2012 - 2020) Division President, Novartis Diagnostics AG (NYSE: NVS) (2009 - 2012) CEO & Country President, Novartis AG, Germany (NYSE: NVS) (2006 - 2008) CEO & Country President, Novartis AG, Korea (2003 - 2005) Head of Division (Franchise Infectious Diseases), Novartis AG (2002 - 2003) Head of Strategy (Pharma Division), Novartis AG (2001 - 2002) Associate Principal, McKinsey & Company (1994 - 2001) Key Skills & Qualifications Business and Operations Leadership Experience: Dr. Maag s 20+ years of executive management experience in the pharmaceutical and diagnostic industry including as former CEO of CareDx and as President of Diagnostics qualify him to advise the Board on matters specific to CareDx s business and strategy. Risk Management: Dr. Maag has deep expertise in risk management as he has served as a director of multiple healthcare companies, including Novartis, MiroMatrix Medical, and as the former Chairman and CEO of CareDx. M&A or Corporate Development Experience: Dr. Maag served in positions at Novartis Pharma and Novartis Diagnostics including as Head of Strategy where he was instrumental in the global growth of the organization. During his tenure at CareDx, he has led multiple acquisitions and financial transactions. Other Boards Director, Kyverna Therapeutics (2022 - 2024) Director, MiroMatrix Medical (2021 - 2023), MiroMatrix was acquired by United Therapeutics (Nasdaq: UTHR) in December 2023 Director, Phoenix Pharmahandel (2012 - Present) Director, MolecularMD (2012 - 2020) Director, Chiron France (2009 - 2012) Director, Novartis AG, Germany (2006 - 2008) Director, Zuellig Pharma (2003 - 2005) Director, Novartis, Korea (2003 - 2005) Current Organizations Director, Personalized Medicine Coalition Director, BluLake Ventures LLC Education Ph.D., University of Berlin MSc, University of Heidelberg, University of London